✦ LIBER ✦

The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients

✍ Scribed by Reinhard Stauder

Book ID: 120775582
Publisher: Springer
Year: 2012
Tongue: English
Weight: 398 KB
Volume: 91
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-012-1472-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Limitations of targeted therapy with sor

Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia

✍ Wei, Andrew; Tan, Peter 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 143 KB

Repeated responses of an elderly patient

Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine

✍ Isabel Möller; Sabine Blum; Norbert Gattermann; Rainer Haas; Kerstin Habersang; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 127 KB

Refinement of the international prognost

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)

✍ Germing, U; Hildebrandt, B; Pfeilstöcker, M; Nösslinger, T; Valent, P; Fonatsch, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 168 KB

Results of imatinib mesylate therapy in

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated

P-289 Effect of low-dose cytarabine and

P-289 Effect of low-dose cytarabine and aclarubicin in combination with decitabine on the outcome of patients with high-risk myelodysplastic syndromes

✍ Pian, S.; Duan, L.; Zhu, Y.; Hong, M.; Zhang, R.; Zhang, S.; Liu, P.; Lu, H.; Wu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Assessing the risk of inadvertent radiat

Assessing the risk of inadvertent radiation exposure of pregnant patients during radiation therapy planning and treatment in British Columbia

✍ Caon, Julianna; Olson, Robert; Tyldesley, Scott; Bergman, Alanah; Bobinski, Mary 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 160 KB